



CODEN [USA] : IAJPBB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

<http://doi.org/10.5281/zenodo.4008451>Available online at: <http://www.iajps.com>

Research Article

**STUDY TO KNOW THE PREVALENCE OF RETINOPATHY  
AMONG PATIENTS OF TYPE II DIABETES MELLITUS**<sup>1</sup>Dr Hafiza Asma Riasat Ali, <sup>2</sup>Dr Dania Aijaz, <sup>3</sup>Dr Mansoor Ul Hassan Qureshi<sup>1</sup>CMH Medical and Dental College Lahore<sup>2</sup>Liaquat University of Medical and Health Sciences, Jamshoro<sup>3</sup>Latin American School of Medicine Havana Cuba**Article Received:** June 2020**Accepted:** July 2020**Published:** August 2020**Abstract:**

**Background:** Diabetic retinopathy is the most common complication for each of us and is the foremost source of blindness globally. Diabetic nephropathy is estimated based on the presence of microalbuminuria. Its association with retinopathy is well known in patients of type I diabetes mellitus, but still uncertain in type 2 diabetes. In this study, the incidence of retinopathy was determined in type 2 diabetic patients with and without microalbuminuria.

**Place and Duration:** In the Endocrinology department and Eye Unit I of Mayo Hospital Lahore for one year duration from April 2019 to April 2020.

**Study design:** A cross-sectional study.

**Methods:** 280 type II diabetes mellitus patients were selected from the Diabetes Management Center. Their spot urine microalbuminuria was performed and selectees were alienated into two groups depending on the absence or presence of microalbuminuria. Patients with macroalbuminuria and hypertension are already excluded from the study. All patients underwent retinoscopy and the frequency of microalbuminuria and retinopathy was determined.

**Results:** The age range was 35 to 70 years. 42.5% are men and 57.5% are women. Microalbuminuria was noted in 76(27.1%) of 280 patients with diabetes. The incidence of retinopathy was advanced in subjects with microalbuminuria (44.74%), while it was 23.04% in patients without microalbuminuria.

**Conclusion:** The occurrence of retinopathy increases in the presence of microalbuminuria. No statistically significant relationship was found in this study.

**Key words:** microalbuminuria, diabetic nephropathy, diabetic retinopathy.

**Corresponding author:**

**Dr Hafiza Asma Riasat Ali,**  
CMH Medical and Dental College Lahore

QR code



Please cite this article in press Hafiza Asma Riasat Ali et al, *Study To Know The Prevalence Of Retinopathy Among Patients Of Type Ii Diabetes Mellitus., Indo Am. J. P. Sci, 2020; 07(08).*

**INTRODUCTION:**

Diabetes mellitus is a syndrome in which there is a combination of irregular metabolism, insulin resistance or insulin secretion, or insufficient secretion for compensation of hyperglycemia<sup>1</sup>. Diabetes is one of the leading cause of mortality and morbidity in the world and is the sixth chief reason of mortality in the USA. The USA has over 71,000 deaths annually<sup>2</sup>. The vast majority of patients with diabetes fall into two broad categories: absolute insulin deficiency and insulin secretion, characterized by type 2 diabetes, insufficient type of growth compensation and the presence of insulin resistance. In addition to the two main types, pregnancy and pancreatic disorders, endocrinopathies and drugs, etc are also the causes<sup>3</sup>. Prolonged hyperglycemia promotes glucose reactions with components of the artery wall, resulting in an increase in glycation end products<sup>4</sup>. These products are cross-linked with collagen, which increases the stiffness of the arteries supporting atherosclerosis in the presence of high density lipoproteins (LDL) and cholesterol. In this way, high blood sugar leads to endothelial damage that occurs as microvascular or macrovascular damage. A diabetic patient is sensitive to many complications that cause morbidity and early mortality. Diabetic complications pose a huge burden to healthcare, as poor glycemic control in diabetic patients is also directly related to increased overall healthcare costs. Microvascular disease also has a significant impact on the lives of type II diabetic patients. Diabetic retinopathy is the most serious of the various complications of diabetes<sup>5-6</sup>. The incidence of diabetic retinopathy is 21% to 60%, respectively, in people with diabetes below five years and at least 15 years. Proliferative retinopathy ranges from 1.2% to 67% in people with diabetes for less than a decade and for 35 or more years. The incidence of blindness was 16% in patients with DM. Retinopathy after ten years of diabetes is associated with longer hemoglobin glycine and proteinuria, increase diastolic pressure and infertility in males<sup>7</sup>.

Renal diseases linked with type II diabetes mellitus is the major cause of end stage renal disease in the world. In the USA, the incidence of renal diseases linked with diabetes mellitus has augmented by 150% over the last ten years. The 1st clinical indication of renal dysfunction in diabetic patients is usually microalbuminuria, which progresses between two to five percent annually<sup>8-9</sup>. Microalbuminuria rarely reversible in type II diabetes, but in its place 20 to 40 percent of patients exceed proteinuria. In 10 to 50 percent of CKD patients and proteinuria finally needs transplantation or dialysis. 40 to 50 percent of diabetic patients with microalbuminuria sooner or

later die of cardiovascular anomalies; this ratio is 3 times greater from cardiac causes, with diabetes, but without signs of renal disease. In cases of the renal disease and diabetes mellitus, decreasing blood pressure and reduced albumin in urine are operative in declining the risk of myocardial infarction, end-stage renal disease, stroke and heart failure. Angiotensin II antagonists and ACE inhibitors supposed to be the utmost beneficial antihypertensive agents. Calcium channel blockers other than dihydropyridine also reduce urine albumin and the advancement of kidney disease, and the grouping of calcium channel blockers and dihydropyridine other than ACE inhibitor treatment is even more effective<sup>10</sup>. Many studies have shown that microalbuminuria is related with the retinopathy in people with diabetes mellitus and the appearance of proliferative diseases in young people. People with microalbuminuria are more likely to have retinopathy than people without microalbuminuria. This data propose that microalbuminuria may be an indicator of the proliferative retinopathy risk.

**PATIENTS AND METHODS:**

This cross-sectional study was completed at the Endocrinology department and Eye Unit I of Mayo Hospital Lahore for one year duration from April 2019 to April 2020. The calculated sample size was 280 cases with a 5% error margin, taking predictable microalbuminuria percentage in type II diabetes mellitus i.e. 25.9% (minimum frequency between variables). All men and women aged 25 to 70 with type 2 diabetes with random sugar > 200 mg / ml or fasting sugar > 126 mg / dl were included for the study. Laser retinal therapy, patients on ACE inhibitors, blood pressure > 140/90, positive protein on dipstick (macroalbuminuria), BUN > 20 mg / dl and creatinine > 1.20 mg / dl and with WBC cast, tubular cast and RBC cast on urine microscopy were omitted from the analysis.

**Data collection:** Patients meeting the inclusion criteria were selected after obtaining informed consent. All information was collected using a specially designed proforma. The form contained demographic information such as name, age and gender. Microalbuminuria was confirmed in spot urine (threshold <28 mg / L). Into 2 groups; Patients were divided according to the absence or presence of microalbuminuria. Retinoscopy was then performed using a retinoscope to detect evidence of diabetic retinopathy ((dot and blot hemorrhages, microaneurysm, soft and hard exudates, venous beading and looping, maculopathy and formation of new vessels). Effect regulators such as age, poor HbA1c glycemic control and treatment used were controlled by stratification.

**RESULTS:**

A total of 280 patients with type 2 diabetes mellitus diagnosed over 10 years were selected from the

Endocrinology department. Table 1 shows that 42.5% of 280 patients are men and 57.5% are women.

**Table 1: Gender of patient**

Gender	Frequency	%age
Male	119	42.5%
Female	161	57.5%

The total percentage of women was higher than men. Table 2 shows the age distribution of patients. According to him, the majority of patients with diabetes were aged 45-64 (70%). Few patients were reported at the extremes of the age groups with a minimum age of 35 years and a maximum of 70 years. The mean age was  $53.20 \pm SD 8.10$ .

**Table 2: Frequency and percentages of age groups**

Age in years	Frequency	%age
35-44	56	20.0%
45-55	114	40.7%
56-64	82	29.3%
65-70	28	10.0%

Table 3 shows the prevalence of microalbuminuria among 76 (27.1%) of 280 patients with microalbuminuria among type II diabetics and not detected in 204 (72.9%).

**Table 3: Frequency of microalbuminuria**

Microalbuminuria	Frequency	%age
Yes	76	27.1%
No	204	72.9%

Table 4 shows the frequency of retinopathy among type 2 diabetics. 86 (30.7%) of 280 patients have retinopathy and 194 (69.3%) did not have retinopathy.

**Table 4: Frequency of retinopathy**

Retinopathy	Frequency	%age
Yes	86	30.7%
No	194	69.3%

Table 5 shows a cross table of microalbuminuria and retinopathy in Table 2x2, 34 of 86 (44.74%) patients with microalbuminuria had retinopathy and the remaining 42 (55.26%) had no retinopathy. It is clear that patients with microalbuminuria have a higher retinopathy (44.74%) than patients without microalbuminuria (23.04%).

**Table 5: Frequency of 'Retinopathy' in patients with and without 'Microalbuminuria'**

Microalbuminuria	Percentage retinopathy		Total
	Yes	No	
Yes	34 (44.74%)	42 (55.26%)	76(100%)
No	47 (23.04%)	157 (76.96%)	204(100%)
<b>Total</b>	81	199	280

**DISCUSSION**

The incidence of diabetes is growing rapidly in our world. Because it is a chronic disease, most of its morbidity and mortality are associated with complications associated with long-term treatment. According to the WHO, 170 million people globally are affected with diabetes and by 2030; it will progress to the 370 million. About 1/3<sup>rd</sup> of those will progressively have worsened kidney function. The 1st clinical indication of renal dysfunction in diabetic patients is usually microalbuminuria, which progresses between two

to five percent annually. Microalbuminuria rarely reversible in type II diabetes, but in its place 20 to 40 percent of patients exceed proteinuria. Blindness is the most terrifying complication of diabetes<sup>11</sup>. In 2002, 124 million people suffered visual impairment, and 37 million were blind. In western countries, diabetes is an important cause of blindness among young patients<sup>12</sup>. The pathogenesis of diabetic retinopathy and nephropathy is the same, therefore it is assumed that microalbuminuria can be used as a predictor of retinopathy and can be used as a marker to identify

patients for detecting retinopathy. A study was conducted to determine the microalbuminuria frequency in type 2 diabetes and to determine the frequency of DR with and without microalbuminuria<sup>13</sup>. Various studies have been performed to evaluate the incidence of microalbuminuria and retinopathy in type 2 diabetes with a prevalence of retinopathy of 16 to 53.4%. In one study, the incidence of diabetic retinopathy was 44.74%. In our study, the incidence of microalbuminuria was 27.1%. Parving *et al.* In type 2 diabetes, the incidence of microalbuminuria was reported as 22% and Lunetta as 15%. In another study, the incidence of microalbuminuria was 153 (25.9%) out of 590 patients. Previous studies indicated that there is an important association between microalbuminuria and the degree of retinopathy. Though, there are insufficient studies that oppose this association. Erasmus *et al.* The frequency of microalbuminuria was 54% in men and 59% in women in 113 patients with TYPE 2<sup>14</sup>. The incidence of retinopathy was 16%. They determined that microalbuminuria may not forecast retinopathy and ensues freely of high blood pressure or glycemic control.

This study shows that patients with microalbuminuria have a high frequency of retinopathy, i.e. 44.74%, and patients without microalbuminuria have a low frequency, i.e. 23.03%. The method used to measure microalbuminuria also has a significant impact on the difference in the frequency of microalbuminuria. In my study, the immunoturbiditic method was used and only one sample was sent for microalbuminuria, but in Manaviat Clinitek analysis 100 samples (Bayer Corporation-Elkhart, USA) was used to study microalbuminuria. Three samples of urine were taken for 3 to 6 months, and if 2 samples were positive, microalbuminuria was indicated. In this study, the method of measuring microalbuminuria is simple and inexpensive, and the results did not differ significantly from the results measured three times in microalbuminuria<sup>15</sup>. This study shows the incidence of retinopathy in patients with and without microalbuminuria, which clearly shows that the frequency of retinopathy increases in the presence of microalbuminuria. More research is needed to better understand the relationship between microalbuminuria and retinopathy. Understanding this relationship will allow a better understanding of the pathophysiology of microvascular diabetic complications. This will enable us to offer new treatments and diagnoses that can reduce morbidity and mortality due to complications of microvascular diabetes.

### CONCLUSION:

This study shows that patients with microalbuminuria develop retinopathy more often than people without microalbuminuria. However, it is uncertain whether microalbuminuria can be used as a forecaster of the presence of diabetic retinopathy in patients with type 2 diabetes, and more research is needed in one or more potential patients with type 2 diabetes to confirm its effectiveness. If it turns out to be effective, you can be referred to an ophthalmologist in the early stages of retinopathy.

### REFERENCES:

1. Zubair A, Mateen FE, Hafeez S, Ali H, Waheed K, Ahmad A. Diabetic Retinopathy Among Type II Diabetics; with and without Microalbuminuria. *Annals of Punjab Medical College (APMC)*. 2019 Sep 28;13(3):236-40.
2. Hangaard S, Rasmussen A, Almdal T, Nielsen AA, Nielsen KE, Siersma V, Holstein P. Standard complication screening information can be used for risk assessment for first time foot ulcer among patients with type 1 and type 2 diabetes. *Diabetes research and clinical practice*. 2019 May 1;151:177-86.
3. Shi R, Niu Z, Wu B, Zhang T, Cai D, Sun H, Hu Y, Mo R, Hu F. Nomogram for the Risk of Diabetic Nephropathy or Diabetic Retinopathy Among Patients with Type 2 Diabetes Mellitus Based on Questionnaire and Biochemical Indicators: A Cross-Sectional Study. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2020;13:1215.
4. Stratigou T, Vallianou N, Koutroumpi S, Vlassopoulou B, Apostolou T, Tsagarakis S, Ioannidis G. Progression of Albuminuria Among Patients with Type 1 Diabetes Mellitus: A Long Term Observational Follow-up Study. *Experimental and Clinical Endocrinology & Diabetes*. 2019 Feb 25.
5. Babaliche P, Nadpara RA, Maldar A. Association Between Estimated Glomerular Filtration Rate and Microvascular Complications in Type II Diabetes Mellitus Patients: A 1-Year Cross-Sectional Study. *Journal of the National Medical Association*. 2019 Feb 1;111(1):83-7.
6. Tanaka N, Yamamoto Y, Yokoyama Y, Mori T, Hanai K, Babazono T. Temporal trends in the prevalence of albuminuria and reduced eGFR in Japanese patients with type 2 diabetes. *Diabetology international*. 2019 Oct 1;10(4):279-87.
7. Blum J, Chaney M, Mudji J, Mfungwa JA, Rice T, Labhardt ND. Glycaemic control among patients with type 2 diabetes followed in a rural African primary care setting—A reality check in the Democratic Republic of Congo. *Primary care diabetes*. 2019 Aug 24.

8. Shahwan MJ, Gacem SA, Zaidi SK. Prevalence of diabetic nephropathy and associated risk factors among type 2 diabetes mellitus patients in Ramallah, Palestine. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2019 Mar 1;13(2):1491-6.
9. Albeltagy ES, Hammour AE, Albeltagy SA. Potential value of serum Progranulin as a biomarker for the presence and severity of micro vascular complications among Egyptian patients with type 2 diabetes mellitus. *Journal of Diabetes & Metabolic Disorders*. 2019 Jun 1;18(1):217-28.
10. Moriya T, Yamagishi T, Matsubara M, Ouchi M. Serial renal biopsies in normo- and microalbuminuric patients with type 2 diabetes demonstrate that loss of renal function is associated with a reduction in glomerular filtration surface secondary to mesangial expansion. *Journal of Diabetes and its Complications*. 2019 May 1;33(5):368-73.
11. Park HC, Lee YK, Cho A, hoon Han C, Noh JW, Shin YJ, Bae SH, Kim H. Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. *PLoS one*. 2019;14(7).
12. Bulum T, Lovrenčić MV, Tomić M, Vučković-Rebrina S, Roso V, Kolarić B, Vuksan V, Duvnjak L. Serum adipocytokines are associated with microalbuminuria in patients with type 1 diabetes and incipient chronic complications. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2019 Jan 1;13(1):496-9.
13. Shikata K, Kodera R, Utsunomiya K, Koya D, Nishimura R, Miyamoto S, Tajima N, JDCP study group. Prevalence of albuminuria and renal dysfunction, and related clinical factors in Japanese patients with diabetes: The Japan Diabetes Complication and its Prevention prospective study 5. *Journal of Diabetes Investigation*. 2020 Mar;11(2):325-32.
14. Sheikh M, Khaliq SA, Khan TA, Mohiuddin E, Usman R. Evaluation of the secondary complications in patients of type-II diabetes mellitus (TIIDM) on allopathic, alternative or combination of medicine system: A cross sectional study. *Pakistan Journal of Pharmaceutical Sciences*. 2019 Nov 2;32.
15. Garg P, Mishra S, Mullick R. A Correlative Study of Duration of diabetes mellitus, microalbuminuria, hyperlipidemia with the severity of diabetic retinopathy. *International Journal of Ophthalmic Research*. 2019 May 12;5(1):308-13.